International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 001-008
THE EVALUATION OF THE PATIENTS WITH NEUROBLASTOMA IN ÇUKUROVA REGION
İBRAHİM BAYRAM1, ATİLLA TANYELİ1, İLGEN ŞAŞMAZ1, BÜLENT ANTMEN1, REFİK BURGUT1, DİNÇER YILDIZDAŞ1, LEVENT YILMAZ1, SÜREYYA SOYUPAK1, NURDAN TUNALI1, YURDANUR KILINÇ1
Çukurova Üniversitesi, Tıp Fakültesi, Pediatrik Hematoloji-Onkoloji BD
Keywords: neuroblastoma, ganglioneuroblastoma
This study was carried out at Çukurova University, Department of Pediatric Hematology-Oncology between January 1991 and March 2001 and 57 patients who were diagnosed with neuroblastoma or ganglioneuroblastoma were included in the study. This study was planned to be a retrospective analysis. Thirty-five of 57 patients (61.4%) were boys, 22 of them (38.6%) were girls. They were in the ages between 2-132 months (average 49.4 ± 37.9 months). In 80.8 % of patients, the tumor was located intraabdominaly. Ninety-eight percent were stage IV (55 patients), one patient was (1.8%) stage III and one patient (1.8%) was stage IVS. Overall survival (OS) for 12 months was 70%, OS for 18 months was 50% and OS for 24 months was 22%. Event free survival was 17%, 15%, 11% respectively. The same ratio was observed until 120 months.
İBRAHİM BAYRAM1, ATİLLA TANYELİ1, İLGEN ŞAŞMAZ1, BÜLENT ANTMEN1, REFİK BURGUT1, DİNÇER YILDIZDAŞ1, LEVENT YILMAZ1, SÜREYYA SOYUPAK1, NURDAN TUNALI1, YURDANUR KILINÇ1
Çukurova Üniversitesi, Tıp Fakültesi, Pediatrik Hematoloji-Onkoloji BD
Keywords: neuroblastoma, ganglioneuroblastoma
This study was carried out at Çukurova University, Department of Pediatric Hematology-Oncology between January 1991 and March 2001 and 57 patients who were diagnosed with neuroblastoma or ganglioneuroblastoma were included in the study. This study was planned to be a retrospective analysis. Thirty-five of 57 patients (61.4%) were boys, 22 of them (38.6%) were girls. They were in the ages between 2-132 months (average 49.4 ± 37.9 months). In 80.8 % of patients, the tumor was located intraabdominaly. Ninety-eight percent were stage IV (55 patients), one patient was (1.8%) stage III and one patient (1.8%) was stage IVS. Overall survival (OS) for 12 months was 70%, OS for 18 months was 50% and OS for 24 months was 22%. Event free survival was 17%, 15%, 11% respectively. The same ratio was observed until 120 months.